Mass Tort Litigation in the U.S. Personal Injury System
Mass tort litigation occupies a distinct and structurally complex position within U.S. civil law, allowing large numbers of individual plaintiffs who suffered similar injuries from a common source to pursue claims without merging those claims into a single collective action. This page covers the definition of mass torts, the procedural mechanisms that govern them, the most frequently litigated categories, and the legal boundaries that distinguish mass torts from related group litigation formats. Understanding this framework matters because the procedural choices made at the outset of a mass tort directly shape damages recoveries, evidentiary standards, and the timeline plaintiffs face.
Definition and scope
A mass tort arises when a single product, substance, event, or course of conduct causes injury to a large group of people, each of whom retains an individual claim with distinct facts about causation, injury severity, and damages. Unlike a class action lawsuit, where a representative plaintiff litigates on behalf of a certified class and the judgment binds all class members, mass tort plaintiffs maintain separate, individualized cases that are coordinated for efficiency but adjudicated on their own merits.
The distinction is doctrinal, not merely procedural. Federal Rule of Civil Procedure 23 governs class certification and imposes requirements — including commonality, typicality, and adequacy of representation — that mass torts frequently cannot satisfy because injury variations among plaintiffs are too significant. Mass torts bypass Rule 23 certification, which means each plaintiff must prove individual causation and damages rather than relying on class-wide findings.
Scope is typically defined by three elements: (1) a shared defendant or set of defendants, (2) a common defective product, hazardous substance, or tortious event, and (3) a substantial number of claimants — often in the thousands or tens of thousands — whose injuries share a common origin. The tort law foundations underlying mass tort claims draw primarily on product liability, negligence, and strict liability theories.
How it works
Mass torts move through the U.S. court system using a layered procedural architecture designed to balance efficiency with the preservation of individual rights.
Phase 1 — Case filing and consolidation
Individual plaintiffs file complaints in federal or state court. When federal cases arise from the same product or event and are pending in multiple districts, the Judicial Panel on Multidistrict Litigation (JPML) — authorized under 28 U.S.C. § 1407 — may transfer cases to a single district court for coordinated pretrial proceedings. This creates what practitioners call an MDL, or multidistrict litigation docket.
Phase 2 — Pretrial coordination
The transferee judge manages consolidated discovery, including depositions of corporate defendants, document production, and expert witness retention. Bellwether trials — a defined subset of representative cases selected to test legal theories and damages ranges — are typically scheduled during this phase.
Phase 3 — Bellwether trials
Bellwether cases are tried individually before juries. Their outcomes provide data about how juries respond to specific evidence, which plaintiffs' attorneys and defense counsel both use to calibrate settlement positions across the broader docket.
Phase 4 — Global resolution or continued litigation
Bellwether results often drive global settlement negotiations. A defendant may establish a settlement fund administered by a third-party claims administrator, with individual payouts determined by settlement grid criteria tied to injury severity, age, and documented exposure duration. Cases that do not settle proceed individually to trial.
The burden of proof in each individual mass tort case remains the civil preponderance of the evidence standard — plaintiff must show it is more likely than not that the defendant's conduct caused the specific injury alleged.
Common scenarios
Mass tort litigation concentrates in five identifiable product and exposure categories:
- Pharmaceutical and medical device defects — Drugs approved by the U.S. Food and Drug Administration (FDA) that later produce widespread adverse effects generate mass tort dockets. Examples include litigation over prescription opioids coordinated under MDL No. 2804 in the Northern District of Ohio and transvaginal mesh litigation (MDL No. 2325). FDA adverse event reporting under 21 C.F.R. Part 310 and device reporting under 21 C.F.R. Part 803 frequently supply documentary evidence in these cases.
- Toxic exposure and environmental contamination — Claims arising from workplace asbestos exposure, contaminated groundwater, or industrial chemical releases involve long latency periods between exposure and diagnosis. The Environmental Protection Agency (EPA) CERCLA framework (42 U.S.C. § 9601 et seq.) identifies responsible parties at contaminated sites, records that frequently appear in tort discovery.
- Consumer product defects — Defective household products, vehicle components, or industrial equipment triggering Consumer Product Safety Commission (CPSC) recalls commonly anchor mass tort claims. The CPSC maintains a public recall database under authority of the Consumer Product Safety Act (15 U.S.C. § 2051).
- Occupational disease — Coal dust, silica, benzene, and similar occupational exposures generate claims governed in part by Occupational Safety and Health Administration (OSHA) permissible exposure limits established under 29 C.F.R. Part 1910.
- Mass disaster events — Plane crashes, building collapses, or large-scale industrial accidents producing a defined group of injured plaintiffs may consolidate into mass tort dockets. Wrongful death claims arising from mass disasters are structured under applicable state wrongful death statutes.
Decision boundaries
Mass tort vs. class action
The operative boundary is individual versus common predominance. Under Rule 23(b)(3), class certification requires that common questions of law or fact predominate over individual ones. Courts have consistently found that personal injury mass tort claims fail this test because individual causation and injury severity require separate proof for each plaintiff. In Amchem Products, Inc. v. Windsor, 521 U.S. 591 (1997), the U.S. Supreme Court decertified an asbestos class settlement class on predominance grounds, establishing that mass personal injury claims are structurally ill-suited to class treatment.
Mass tort vs. individual personal injury
The distinction is scale and coordination mechanism, not legal theory. A single plaintiff alleging injury from a defective drug pursues the identical negligence or strict liability theories available in mass tort. The practical difference is that individual plaintiffs lack the consolidated discovery infrastructure and bellwether data that mass tort dockets generate, placing a heavier research burden on counsel and plaintiffs independently.
State court mass torts
Not all mass torts reach federal MDL. When defendants are non-diverse or plaintiffs file in a single state, state court consolidation statutes govern. New Jersey, California, and Pennsylvania each have formal mass tort programs. New Jersey's Complex Business Litigation Program, administered under Rule 4:38A of the New Jersey Court Rules, explicitly addresses pharmaceutical and products mass tort dockets.
Statute of limitations considerations
Mass tort claims remain subject to state-specific statutes of limitations and, in product cases, statutes of repose. Tolling doctrines — particularly the discovery rule, which delays the limitations clock until a plaintiff knows or reasonably should know of the injury and its probable cause — are particularly significant in latent disease cases where diagnosis may occur decades after exposure. Tolling rules are analyzed under state law on a claim-by-claim basis even within consolidated federal MDL proceedings.
Damages structure
Each plaintiff in a mass tort retains the right to pursue individualized compensatory damages and, where applicable, punitive damages. Settlement grids in global resolution programs typically set compensation tiers based on injury classification — for example, distinguishing mesothelioma from pleural plaques in asbestos litigation, or separating revision surgery from non-revision outcomes in medical device cases. State damage caps apply to applicable claims and are not preempted by MDL consolidation.